Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial
Jasper Tromp, Piotr Ponikowski, Afshin Salsali, et al.
European Journal of Heart Failure (2021) Vol. 23, Iss. 5, pp. 826-834
Open Access | Times Cited: 85

Showing 1-25 of 85 citing articles:

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
Adriaan A. Voors, Christiane E. Angermann, John R. Teerlink, et al.
Nature Medicine (2022) Vol. 28, Iss. 3, pp. 568-574
Open Access | Times Cited: 649
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
Scott D. Solomon, Rudolf A. de Boer, David L. DeMets, et al.
European Journal of Heart Failure (2021) Vol. 23, Iss. 7, pp. 1217-1225
Open Access | Times Cited: 274
Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)
P. Christian Schulze, Jürgen Bogoviku, Julian Westphal, et al.
Circulation (2022) Vol. 146, Iss. 4, pp. 289-298
Open Access | Times Cited: 152
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
Jan Biegus, Adriaan A. Voors, Sean P. Collins, et al.
European Heart Journal (2022) Vol. 44, Iss. 1, pp. 41-50
Open Access | Times Cited: 140
Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure
Joyce Njoroge, John R. Teerlink
Circulation Research (2021) Vol. 128, Iss. 10, pp. 1468-1486
Open Access | Times Cited: 139
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial
Mikhail Kosiborod, Christiane E. Angermann, Sean P. Collins, et al.
Circulation (2022) Vol. 146, Iss. 4, pp. 279-288
Open Access | Times Cited: 119
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
Daniela Tomasoni, Gregg C. Fonarow, Marianna Adamo, et al.
European Journal of Heart Failure (2021) Vol. 24, Iss. 3, pp. 431-441
Open Access | Times Cited: 108
Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis
Husam M. Salah, Subhi J. Al’Aref, Muhammad Shahzeb Khan, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 68
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial
Adriaan A. Voors, Kevin Damman, John R. Teerlink, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 10, pp. 1844-1852
Open Access | Times Cited: 61
The Win Ratio Method in Heart Failure Trials: Lessons Learnt From Empulse
Stuart J. Pocock, João Pedro Ferreira, Timothy Collier, et al.
European Journal of Heart Failure (2023) Vol. 25, Iss. 5, pp. 632-641
Open Access | Times Cited: 25
Guideline-Directed Medical Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction
Jay Patel, Negin Rassekh, Gregg C. Fonarow, et al.
Drugs (2023) Vol. 83, Iss. 9, pp. 747-759
Closed Access | Times Cited: 25
Sodium–glucose cotransporter‐2 inhibitors in heart failure: Potential decongestive mechanisms and current clinical studies
Jan Biegus, Marat Fudim, Husam M. Salah, et al.
European Journal of Heart Failure (2023) Vol. 25, Iss. 9, pp. 1526-1536
Open Access | Times Cited: 24
2024 Clinical practice guidelines for Chronic heart failure
А. S. Galyavich, S. N. Tereshchenko, T. M. Uskach, et al.
Russian Journal of Cardiology (2024) Vol. 29, Iss. 11, pp. 6162-6162
Open Access | Times Cited: 12
Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction – Results from the EMPULSE trial
Jasper Tromp, Mikhail Kosiborod, Christiane E. Angermann, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 4, pp. 963-970
Open Access | Times Cited: 9
Heart Failure Pharmacological Management: Gaps and Current Perspectives
Paolo Severino, Andrea D’Amato, Silvia Prosperi, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 3, pp. 1020-1020
Open Access | Times Cited: 21
Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians
Luca Monzo, Ilaria Ferrari, F Cicogna, et al.
European Heart Journal Supplements (2023) Vol. 25, Iss. Supplement_C, pp. C309-C315
Open Access | Times Cited: 18
The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction
Nicholas K. Brownell, Boback Ziaeian, Gregg C. Fonarow
Cardiac failure review (2021) Vol. 7
Open Access | Times Cited: 41
Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors
David Z.I. Cherney, Jacob A. Udell, Daniel J. Drucker
Med (2021) Vol. 2, Iss. 11, pp. 1203-1230
Open Access | Times Cited: 36
SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis
Victor Razuk, Mauro Chiarito, Davide Cao, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2022) Vol. 8, Iss. 6, pp. 557-567
Closed Access | Times Cited: 28
In-hospital Initiation and Up-titration of Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction
Zachary L. Cox, Shuktika Nandkeolyar, Andrew J. Johnson, et al.
Cardiac failure review (2022) Vol. 8
Open Access | Times Cited: 28
Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease
Riccardo Nevola, Maria Rosaria Alfano, Pia Clara Pafundi, et al.
Reviews in Cardiovascular Medicine (2022) Vol. 23, Iss. 3
Open Access | Times Cited: 25
Temporal Trends of Heart Failure Hospitalizations in Cardiology Versus Noncardiology Wards According to Ejection Fraction: 16-Year Data From the SwedeHF Registry
Marco Canepa, Chris J. Kapelios, Lina Benson, et al.
Circulation Heart Failure (2022) Vol. 15, Iss. 8
Closed Access | Times Cited: 20
SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials
Noor ul Amin, Faiza Sabir, Talal Bin Amin, et al.
Healthcare (2022) Vol. 10, Iss. 12, pp. 2356-2356
Open Access | Times Cited: 20
A practical approach to the guideline‐directed pharmacological treatment of heart failure with reduced ejection fraction
Amr Abdin, Johann Bauersachs, Samira Soltani, et al.
ESC Heart Failure (2022) Vol. 10, Iss. 1, pp. 24-31
Open Access | Times Cited: 19
The clinical outcomes of dapagliflozin in patients with acute heart failure: A randomized controlled trial (DAPA-RESPONSE-AHF)
Abdelrahman N. Emara, Moheb Wadie, Noha O. Mansour, et al.
European Journal of Pharmacology (2023) Vol. 961, pp. 176179-176179
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top